Nautilus is a biotechnology company whose proteomics platform will deliver superior sensitivity far more quickly, more completely, and less expensively than is currently possible. By breaking through the limitations of existing technologies, and effectively democratizing proteomics, Nautilus will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and usher in a new era of personalized and predictive medicine.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/21/20 | $76,000,000 | Series B |
AME Cloud Ventures Bolt Defy Partners Madrona Venture Group Perceptive Advisors Vulcan Capital  | undisclosed |
